Post Profile






Frontline PARP inhibitor shrinks tumors in BRCA-positive breast patients

(University of Texas M. D. Anderson Cancer Center) All 13 newly diagnosed breast cancer patients with BRCA mutations had their tumors shrink significantly when treated with a PARP inhibitor ahead of frontline presurgical chemotherapy in a pilot study at The University of Texas MD Anderson Cancer Center.
read more

share

Related Posts


PARP inhibitor shows activity in pancreatic, prostate cancers among patients carrying BRCA mutations

Academics / General Science : Science Codex

PHILADELPHIA – In the largest clinical trial to date to examine the efficacy of PARP inhibitor therapy in BRCA 1/2 carriers with diseases other than breast and ovarian cancer, the oral drug olaparib was found to be effective against...

Nearly Half of Breast Cancer Patients at High Risk of Carrying BRCA Mutations Do Not Receive Genetic Testing Recommendations from Physicians

Health : Newswise Medical News

Only 53 percent of newly diagnosed breast cancer patients who were at high risk of carrying a BRCA 1 or BRCA 2 mutation - based on age, diagnosis, and family history of breast or ovarian cancer - reported that their doctors urged th...

Genetic Testing Not Carried Out For Nearly Half Of Breast Cancer Patients At Risk Of Having BRCA Mutations

Health : Medical News Today

Only 53 percent of newly diagnosed breast cancer patients who were at high risk of carrying a BRCA 1 or BRCA 2 mutation - based on age, diagnosis, and family history of breast or ovarian cancer - reported that their doctors urged th...

Daughters With BRCA Gene Diagnosed With Breast Cancer 8 Years Younger Than Their Mothers Were

Health : Medical News Today

A female today who has a BRCA gene mutation is being diagnosed with breast and ovarian cancer about eight years earlier than their mothers or aunts were, researchers from the University of Texas MD Anderson Cancer Center reported in...

Among Patients Carrying BRCA Mutations, PARP Inhibitor Shows Activity In Pancreatic, Prostate Cancers

Health : Medical News Today

In the largest clinical trial to date to examine the efficacy of PARP inhibitor therapy in BRCA 1/2 carriers with diseases other than breast and ovarian cancer, the oral drug olaparib was found to be effective against advanced pancr...

Comments


Copyright © 2016 Regator, LLC